ANIXA BIOSCIENCES, INC. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances
ANIXA BIOSCIENCES, INC. (ANIX) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances of $1.57 million for the 9-month period ending 2014-07-31, per its 10-Q filed 2014-09-15.
Discontinued › Notes › Fair Value Measures and Disclosures › Fair Value Disclosures › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation › Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases, (Sales), Issuances, (Settlements)
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues · last filed 2014-09-15
- ANIXA BIOSCIENCES, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, issuances for the quarter ending 2014-07-31 was $0.00.
- ANIXA BIOSCIENCES, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, issuances for fiscal 2013 was $1.18M.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances 12 month |
|---|---|---|---|---|
| 2014-07-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2014-09-15 | $1.57M 10-Q · filed 2014-09-15 | ||
| 2014-04-30 | $1.57M 10-Q · filed 2014-06-16 | |||
| 2013-10-31 | $1.18M 10-K/A · filed 2014-01-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 |